论文部分内容阅读
目的探讨胸腺五肽联合化疗治疗糖尿病合并结核性胸膜炎的临床疗效。方法将临床确诊的糖尿病合并结核性胸膜炎70例患者随机分为治疗组(n=35)和对照组(n=35);对照组给予常规抗结核药物、调整血糖和胸腔穿刺抽液治疗。治疗组在上述常规治疗的基础上加用胸腺五肽注射液治疗。疗程均为30d。比较两组间治疗后空腹血糖、体温恢复正常时间、胸水吸收时间、胸痛缓解时间。结果治疗组治疗后空腹血糖、胸水吸收时间均优于对照组,两组比较,差异有统计学意义(P<0.01);两组间在体温恢复时间、胸痛缓解时间比较,差异无统计学意义(P>0.05)。结论胸腺五肽联合化疗治疗糖尿病合并结核性胸膜炎可促进空腹血糖控制、促进胸水吸收,疗效显著,且无不良反应。
Objective To investigate the clinical efficacy of thymopentin combined with chemotherapy in the treatment of diabetic patients with tuberculous pleurisy. Methods Seventy patients with clinically diagnosed diabetes mellitus complicated with tuberculous pleurisy were randomly divided into treatment group (n = 35) and control group (n = 35). The control group was given conventional antituberculous drugs and blood glucose and thoracentesis aspiration therapy. The treatment group on the basis of the above conventional treatment with thymopentin injection. Treatment are 30d. Fasting blood glucose, body temperature recovery time, pleural effusion absorption time, chest pain relief time were compared between the two groups. Results After treatment, fasting blood glucose and pleural effusion absorbed time in treatment group was better than that in control group, there was significant difference between the two groups (P <0.01). There was no significant difference between the two groups in recovery time of body temperature and chest pain relief time (P> 0.05). Conclusion Thymopentin combined with chemotherapy for the treatment of diabetic patients with tuberculous pleurisy can promote fasting blood glucose control and promote the absorption of pleural fluid with significant curative effect and no adverse reactions.